EDAP TMS Reports Flat $70.5M Revenue, $(0.78) Annual Loss Per Share
Summary
EDAP TMS SA filed its 10-K, reporting fiscal year revenue of $70.5 million, which was essentially flat year-over-year, and a basic loss per share of $(0.78). This detailed financial disclosure follows an earlier 8-K filing today that highlighted strong Q4 and full-year HIFU business growth. Despite the operational growth, the overall financial results show a significant net loss of $29.2 million. The company also noted $20.45 million in cash and cash equivalents, with an expected Tranche B draw to support operations for at least 12 months, indicating a reliance on future financing. This flat revenue and substantial loss are material for a company of EDAP's market capitalization, and traders will be watching for updates on the expected financing and the company's ability to achieve its projected revenue expansion and margin improvement.
At the time of this announcement, EDAP was trading at $3.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.2M. The 52-week trading range was $1.21 to $5.05. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.